Literature DB >> 6331926

Prostaglandin E2 depresses natural cytotoxicity by inhibiting interleukin-1 production by large granular lymphocytes.

J Herman, A R Rabson.   

Abstract

Enriched large granular lymphocytes treated with varying concentrations of prostaglandin E2 (PGE2) for varying time periods showed considerably reduced natural cytotoxicity against K-562 target cells. The same cells when activated by lipopolysaccharide, produced substantially less interleukin-1 (IL-1) as compared to cells not treated with PGE2. It is concluded that the inhibition of natural killer (NK) cell activity produced by PGE2 is due to inhibition of IL-1 production by these cells.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6331926      PMCID： PMC1536132     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  11 in total

1.  Inhibition of murine natural killer cell activity by prostaglandins.

Authors:  M J Brunda; R B Herberman; H T Holden
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

2.  A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells.

Authors:  M J Droller; M U Schneider; P Perlmann
Journal:  Cell Immunol       Date:  1978-08       Impact factor: 4.868

3.  Prostaglandin E2 rather than lymphocyte-activating factor produced by activated human mononuclear cells stimulates increases in murine thymocyte cAMP.

Authors:  J J Oppenheim; W J Koopman; L M Wahl; S F Dougherty
Journal:  Cell Immunol       Date:  1980-01       Impact factor: 4.868

4.  Prostaglandins from tumours of human large bowel.

Authors:  A Bennett; M D Tacca; I F Stamford; T Zebro
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

5.  The modulation of human natural killer cell activity by prostaglandins.

Authors:  A D Bankhurst
Journal:  J Clin Lab Immunol       Date:  1982-02

6.  Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells.

Authors:  G Trinchieri; D Santoli; D Granato; B Perussia
Journal:  Fed Proc       Date:  1981-10

7.  Human lymphocytic metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin.

Authors:  J W Smith; A L Steiner; C W Parker
Journal:  J Clin Invest       Date:  1971-02       Impact factor: 14.808

8.  Breast cancer, prostaglandins, and bone metastases.

Authors:  A Bennett; A M McDonald; J S Simpson; I F Stamford
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

9.  The effects of cyclic AMP on leucocyte inhibitory factor (LIF) production and on the inhibition of leucocyte migration.

Authors:  R Lomnitzer; A R Rabson; H J Koornhof
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

10.  Mechanism of inhibition of tumour growth by aspirin and indomethacin.

Authors:  N R Lynch; M Castes; M Astoin; J C Salomon
Journal:  Br J Cancer       Date:  1978-10       Impact factor: 7.640
View more
  4 in total

1.  Monocyte factors modulate in vitro T-lymphocyte mitogenesis in protein malnutrition.

Authors:  R C Bell; L Hoffman-Goetz; R Keir
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

2.  Regulation of human natural killer (NK) cell function: induction of killing of an NK-resistant renal carcinoma cell line.

Authors:  M C Kanar; D L Thiele; M Ostensen; P E Lipsky
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

3.  Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.

Authors:  R S Parhar; P K Lala
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

4.  Cytokine gene regulation by PGE(2), LTB(4) and PAF.

Authors:  M Rola-Pleszczynski; J Stankova
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.